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Misactivation of the seven-transmembrane protein
Smoothened (Smo) is frequently associated with
basal cell carcinoma and medulloblastoma. Cellular
exposure to secreted Hedgehog (Hh) protein or
oncogenic mutations in Hh pathway components
induces Smo accumulation in the primary cilium, an
antenna-like organelle with mostly unknown cellular
functions. Despite the data supporting an indis-
pensable role of the primary cilium in Smo activation,
the mechanistic underpinnings of this dependency
remain unclear. Using a cell-membrane-imperme-
able Smo antagonist (IHR-1), we demonstrate that
Smo supplied with a synthetic agonist or activated
with oncogenic mutations can signal without ciliary
accumulation. Similarly, cells with compromised
ciliary Smo trafficking due to loss of the phospha-
tidylinositol-4-phosphate 3-kinase (PI3K)-C2a retain
transcriptional response to an exogenously supplied
Smo agonist. These observations suggest that as-
sembly of a Smo-signaling complex in the primary
cilium is not a prerequisite for Hh pathway activa-
tion driven by Smo agonists or oncogenic Smo
molecules.
INTRODUCTION
Small molecules that disrupt the hedgehog (Hh) signal trans-
duction pathway are targeted therapeutic agents with proven
anticancer efficacy (Low and de Sauvage, 2010). The foundation
of this strategy is chemical inhibitors of Smoothened (Smo),
a seven-transmembrane protein with similarity to G-protein-
coupled receptors (GPCRs) that controls through a signaling
cascade the Gli family of DNA-binding proteins. Under homeo-
static conditions, the 12-transmembrane protein Patched
(Ptch) restrains Smo activity when Ptch is not directly bound to
Hh ligand (Ingham and McMahon, 2001). Given the structural
similarity of Ptch to small-molecule transporters and its activity
dependency on residues essential to the action of such trans-1680 Chemistry & Biology 21, 1680–1689, December 18, 2014 ª2014porters, Ptch likely regulates Smo by gating its access to an
endogenous small molecule with Smo-modulatory activity (Bris-
coe and Therond, 2013; Taipale et al., 2002). Misactivation of
Smo in90%of basal cell carcinoma and20%ofmedulloblas-
toma most commonly results from either loss-of-function muta-
tions in PTCH1 (Hahn et al., 1996; Johnson et al., 1996) or gain-
of-function mutations in Smo (Lam et al., 1999; Xie et al., 1998).
Two pockets that support small-molecule-mediated modula-
tion of activity present in Smo further lend support for the exis-
tence of endogenous Smo ligands. One pocket is formed by
the seven-transmembrane (7TM) bundle and another by the
extracellular cysteine-rich domain (CRD). Whereas the 7TM
bundle is accessible to a number of Smo modulators including
the anticancer agent vismodegib and a Smo agonist (SAG)
(Wang et al., 2013, 2014), the CRD-localized pocket binds oxy-
sterols (Myers et al., 2013; Nachtergaele et al., 2013; Nedelcu
et al., 2013; Rana et al., 2013). A model of Smo-dependent regu-
lation by Ptch that emerges from these studies is that the 7TM
bundle constitutes the primary site of Smo regulation by a sub-
strate of Ptch whereas the CRD pocket constitutes an allosteric
site that supports maximal Smo activity.
Activation of the Hh pathway is associated with the accumula-
tion of Smo in the primary cilium, an enigmatic antenna-like
cellular structure found in most cells (Goetz and Anderson,
2010). Efforts to understand the importance of Smo subcellular
redistribution in response to Hh using genetic strategies has
been hindered by the multiple roles that the primary cilium plays
in Hh response including those directly relating to Gli regulation
(Ocbina and Anderson, 2008). For example, mutations in some
intraflagellar trafficking proteins that support ciliary integrity
also inactivate Gli proteins, thus compromising functional anal-
ysis of Smo-cilium relationships (Ocbina and Anderson, 2008).
In addition, the primary cilium is essential to the proteolytic
processing of two of the three Gli protein family members (Gli2
and Gli3) into transcriptional repressors in the absence of Hh
signaling (Huangfu et al., 2003; Liu et al., 2005).
The ability of some Smo agonists and antagonists alike to pro-
mote Smo accumulation in the primary cilium suggests that this
cellular event is not sufficient for pathway activation (Rohatgi
et al., 2009; Wang et al., 2009, 2012). Indeed, these observations
support a two-step model of Smo activation—Smo accumula-
tion in the primary cilium and its adoption of an active conforma-
tion presumably in the primary cilium. Our understanding of howElsevier Ltd All rights reserved
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coupled remains unclear. From a large chemical library screen
intended to expand the number of chemical probes useful for
studying Hh signaling and cilia biology, we identified several
pharmacophores not previously associated with Smo inhibitory
activity. As part of our in-depth study of the most potent com-
pound identified, inhibitor of hedgehog response 1 (IHR-1), we
observed that Smo bypasses the need to accumulate in the pri-
mary cilium for activation when exogenously provided with an
agonist or when it harbors an oncogenic mutation. Using ciliary
protein-trafficking defective cells, we confirm that Smo ciliary
accumulation and its ability to induce Gli activation can be un-
coupled with the introduction of a Smo agonist. These observa-
tions suggest that the assembly of a Smo-signaling complex in
the primary cilium is not essential for oncogenic Smo signaling.
RESULTS
A small collection of Hh-signaling inhibitors (IHR compounds)
was identified from screening a diverse synthetic chemical li-
brary using a cultured cell-based reporter of cell-autonomous
Hh pathway response (Figure 1A and Figure S1A available on-
line). Following a battery of counterscreens to identify specific
Hh pathway inhibitors, we retained several potent compounds
that do not inhibit other signal transduction pathways (Figure 1B;
see Figures S1A and S1B) or disrupt ciliogenesis (Figure S1C)
but do disable Hh-mediated transcriptional induction of endog-
enous targets (Figures S1D and S1E). The seven most-potent
inhibitors (IHR-1–IHR-7) target Smo as measured by their ability
to block Smo binding to Bodipy-cyclopamine (BD-cyclopamine),
a fluorescently labeled Smo antagonist (Figures 1C, S1F, and
S1G). For the most potent of these seven compounds, IHR-1
(Figure 1B), we also demonstrated direct Smo targeting based
on its ability to (1) block Hh-induced movement of Smo into the
primary cilium (Figure 1D), (2) disengage Smo-dependent abro-
gation of Gli2 and Gli3 proteolytic processing (Figures 1E, S2A,
and S2B), and (3) inhibit Gli activity induced by loss of PTCH1
(Figure S2C).
To more directly define the IHR-1-binding site in Smo, we en-
gineered a fluorescently labeled IHR-1 compound that retains
activity against Hh pathway response (IHR-Cy3; Figures 1F
and S3A–S3C). Further establishing the utility of IHR-1 as spe-
cific probes for Smo, we observed IHR-1 activity and Smo bind-
ing are both influenced by its regiochemistry (Figures S3D and
S3E). Similar to the results from studies using BD-cyclopamine,
the Smo agonist SAG is able to abolish IHR-Cy3 labeling of Smo-
expressing cells, suggesting that IHR-1 and SAG compete for
binding to the same pocket formed by the heptahelical bundle
(Figure 1G). Further supporting this conclusion, IHR-Cy3 binding
to Smo was not disrupted by 20(S)-hydroxycholesterol (20(S)-
OHC), which engages the lipid-binding pocket in the Smo CRD
(see Figure 1G; Myers et al., 2013; Nachtergaele et al., 2013; Ne-
delcu et al., 2013).
Surprisingly, despite its potent activity against Hh-induced
pathway activity and its shared binding pocket with SAG, IHR-
1 exhibited a markedly reduced maximal inhibitory response
for SAG-induced pathway activation (a maximal 100-fold excess
of IHR-1 to SAG was evaluated; Figure 2A). Consistent with our
ability to compete away IHR-Cy3 cell labeling with SAG andChemistry & Biology 21, 1680–168further suggesting that IHR-1 does not function as a partial
antagonist is our ability to achieve maximal transcriptional SAG
response in the presence of IHR-1 (Figure S3F). Taken together,
these observations reveal a population of Smo that is activated
by SAG and likely inaccessible to IHR-1. Indeed, SAG is a cell-
permeable compound that is able to penetrate the blood brain
barrier in animal studies, suggesting that SAG may activate an
intracellular pool of Smo inaccessible to IHR-1 (Heine et al.,
2011).
Our synthetic strategy for achieving the IHR-Cy3 molecule
resulted in a derivative (IHR-NAc) that remarkably exhibits
improved maximal inhibitory action against SAG-induced Smo
response (Figure 2B). At the same time, IHR-NAc exhibited
slightly more-potent activity than IHR-1 against Hh-induced
transcriptional response and retained its ability to block BD-cy-
clopamine from binding Smo as compared to IHR-1 (see Figures
2B and S4A). Supporting little change in their ability to attack
Smo, IHR-1 and IHR-NAc inhibited activity associated with
overexpressed wild-type Smo with equal potency (Figure 2C).
A difference in the ability of IHR-1 and IHR-NAc to access an
intracellular pool of active Smo could explain the poor maximal
inhibitory activity of IHR-1 in the presence of SAG. We directly
measured the relative cell permeability of IHR-1 and IHR-NAc
using a workhorse assay for assessing chemical cell perme-
ability based upon the ability of a molecule of interest to cross
a monolayer of Caco-2 cells that form cell-cell tight junctions
(Figure 2D; Li et al., 2007). Our results from this study revealed
that IHR-NAc exhibited superior ability as compared to IHR-1
to traverse a cell monolayer (Figure 2E). As Caco-2 cells are
derived from the gut and may also utilize active transport mech-
anisms for drug absorption, we executed a similar test using
another workhorse assay for monitoring cell permeability (paral-
lel artificial membrane permeability [PAMPA]; Figures 2F and
2G). Both Caco-2 and PAMPA results provide evidence that
breaking the symmetry of IHR-1 by changing a chlorine atom
into a hydrogen bond donor/acceptor in IHR-1 markedly im-
proves its cell penetration without compromising its ability to
inhibit Smo (Figure 2H). Furthermore, we confirm that SAG is
membrane permeable using PAMPA.
The majority of an oncogenic form of Smo (SmoM2) when
overexpressed in cultured cells is localized to the ER likely as
a consequence of its compromised ability to fold due to the
W535L substitution (Chen et al., 2002a). Cell-permeable Smo
agonists and antagonists are able to promote SmoM2 exit
from the ER likely by facilitating protein folding, thereby affording
a fairly universal assay for monitoring intracellular Smo interac-
tion with chemicals binding the Smo heptahelical cavity (Chen
et al., 2002a). In agreement with our assigned relative cell mem-
brane permeability for these chemicals, IHR-NAc, but not IHR-1,
induced SmoM2 protein to exit the ER (Figures S4B–S4D). Our
cellular activity and cell membrane permeability data taken
together reveals a strong correlation between IHR-1/IHR-NAc
cell membrane permeability and their ability to inhibit SAG-
induced Smo activation.
In order to better understand the basis for their different activ-
ities against SAG-induced, but not Hh-induced, pathway res-
ponse, we next evaluated the effects of IHR-1 and IHR-NAc on
several biochemical markers of Hh signaling. Smo activation in-
duces the ciliary depletion of Gpr161, a seven-transmembrane9, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1681
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Figure 1. Identification of IHR-1, an Hh
Pathway Inhibitor that Targets the Hepta-
helical Domain of Smo
(A) Schematic of the screening platform used to
identify Hh pathway antagonists. Compounds
that induced loss of firefly luciferase (FL) activity,
which reports cell-autonomous Hh-dependent Gli
transcriptional activity (GliBS reporter), without
changing levels of a control Renilla luciferase (RL)
in 3T3-ShhFL cells were identified as potential Hh
pathway inhibitors.
(B) IC50 of the seven most potent IHR com-
pounds as determined using the 3T3-ShhFL cells.
Cyclopamine and SANT1 are established Smo
inhibitors.
(C) IHR compounds directly target Smo.
Cells transfected with either Smo or Frizzled 4
(Fzd4) (a Smo-related molecule that functions in
Wnt-mediated signaling) were treated with a flu-
orescently labeled Smo antagonist (BD-cyclop-
amine) in the presence of one of seven IHR
compounds identified from the chemical screen
or a control compound. Percent of Bodipy-
labeled cells were then scored using fluores-
cence-activated cell sorting (FACS) analysis to
determine the ability of unlabeled compounds
(1 mM) to compete with BD-cyclopamine (5 nM)
for Smo binding. Cyclopamine, SANT1, and
SAG directly bind to Smo. IWR-1 is a Wnt/
b-catenin pathway inhibitor and serves as a
negative control.
(D) IHR-1 prevents Smo from accumulating in
the primary cilium. Percent of NIH 3T3 cells with
Smo-GFP colocalizing with acetylated tubulin
(labeling the primary cilium) was quantified (n =
100). Conditioned medium containing ShhN pro-
tein (ShhN CM). Vismodegib is a FDA-approved
Smo antagonist. Data are mean + SEM of three
fields.
(E) IHR-1 blocks Hh-induced suppression of Gli
processing into repressor molecules. Gli3F, full-
length Gli3; Gli3R, Gli3 repressor.
(F) Structures of IHR-1 and a fluorophore-labeled
IHR-1 compound (IHR-Cy3).
(G) IHR-1 and SAG target the Smo heptahelical
pocket. SAG targeting the Smo 7TM domain,
but not 20(S)-hydroxycholesterol (20(S)-OHC)
targeting the extracellular Smo cysteine-rich
domain, competes with IHR-Cy3 for Smo bind-
ing. Cells transfected with either Smo or Fzd4
were treated with 5 mM IHR-Cy3 with and
without 10 mM SAG or 20(S)-OHC. Percent of
Cy3-labeled cells were then scored using FACS
analysis.
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kinase-A-dependent Gli processing (Mukhopadhyay et al.,
2013). Consistent with the effects of IHR-1 and IHR-NAc on
SAG-induced Gli activity, IHR-NAc, but not IHR-1, blocked
SAG-induced Gpr161 ciliary depletion (Figure 3A). Two addi-
tional markers of Hh pathway response—abrogation of Gli pro-1682 Chemistry & Biology 21, 1680–1689, December 18, 2014 ª2014cessing and Gli interaction with its cytoplasmic inhibitory partner
Suppressor of Fused (Sufu)—were further examined to confirm
the differences in the ability of IHR-NAc and IHR-1 to inhibit
SAG-induced pathway response (Figures 3B and S5).
In addition to Gpr161, several other Hh pathway components
exhibit subcellular redistribution upon Hh stimulation includingElsevier Ltd All rights reserved
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Figure 2. Markedly Different Cell Membrane
Permeability of IHR-1 and Its Derivative IHR-
NAc Correlates with Their Ability to Inhibit
SAG-Induced Hh Pathway Activation
(A) IHR-1 is incapable of blocking SAG-induced Hh
pathway response. IC50s of IHR-1 against Hh
pathway response induced by either expression of
Shh or SAG (0.1 mM) treatment were obtained in NIH
3T3 cells transfected with the GliBS reporter. Data
are mean + SEM from triplicate experiments.
(B) The IHR-1 derivative IHR-NAc exhibits greater
maximal inhibitory activity against SAG-induced
pathway response as compared to IHR-1. IHR-NAc
activity in Hh-induced response is similar to that
observed for IHR-1. Data are mean + SEM from
triplicate experiments.
(C) Basal wild-type Smo activity is equally sensitive to
IHR-1 and IHR-NAc. Data are mean + SEM from
triplicate experiments.
(D) Schematic of a transwell assay to measure
cellular permeability of small-molecule modulators of
Smo activity. Smo antagonists are deposited in a
growth chamber that is separated into two chambers
by a monolayer of Caco-2 cells and a porous mem-
brane (0.4 mm).
(E) IHR-NAc exhibits improved ability to transverse
a cell monolayer as compared to IHR-1. Mass
spectrometric analysis of compound levels that have
traversed the Caco-2 cell monolayer for IHR-1 and
IHR-NAc. Indicated compounds (10 mM) were
deposited in the donor well and concentration of
compound found in receiver well determined by
mass spectrometry. Propranolol and nadolol are
typical positive and negative controls for perme-
ability, respectively. Data are mean + SEM from
triplicate experiments with two separate studies
reported.
(F) Schematic of parallel artificial membrane perme-
ability assay (PAMPA). A phospholipid membrane
separates the donor and receiving chambers.
(G) IHR-NAc exhibits improved ability to transverse a
lipid bilayer as compared to IHR-1. Verapamil and
atenolol represent permeable and impermeable
reference molecules, respectively. IHR-NAc exhibits
100-fold greater cell membrane permeability than
IHR-1. n = 3 in each experiment.
(H) Model of IHR-1 and IHR-NAc action in SAG-
stimulated cells. Extracellularly exposed Smo is
accessible to both IHR-1 and IHR-NAc. However,
intracellularly localized activated Smo is accessible
only to the cell-permeable IHR-NAc.
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Extraciliary Smoothened Activation of Hh SignalingGli2 accumulation at the tip of the primary cilium and Smo accu-
mulation throughout the organelle (Goetz and Anderson, 2010).
Perhaps not unexpectedly given the transcriptional response
data presented so far, IHR-NAc, but not IHR-1, blocked Gli2
accumulation at the ciliary tip in response to SAG treatment (Fig-
ure 3C). At the same time, both compounds were equally profi-
cient at inhibiting Smo from accumulating in the primary cilium
in the presence of SAG despite the differences in their ability to
influence SAG-induced Gli activation (Figure 3D). The ability of
IHR-1 and IHR-NAc to block Smo accumulation in the primary
cilium reaffirms our position that both chemicals are able to
bind to Smo in the presence of SAG. More importantly, it reveals
Smo accumulation in the primary cilium can be uncoupled fromChemistry & Biology 21, 1680–168several well-established biochemical and cell biological events
previously associatedwith Smo activity within the primary cilium.
We further investigated this observation using a genetically
based approach. Loss of the phosphoinositide-3-kinase, class
2, alpha (PI3K-C2a) protein results in ciliary trafficking defects
that affect the ability of Smo to accumulate in the primary cilium
in response to Hh protein and SAG (Franco et al., 2014).Whereas
absence of Smo accumulation is associated with compromised
Hh-dependent response in cells with PI3K-C2a loss (Franco
et al., 2014), Smo response to SAG stimulation under these con-
ditions remains untested. Consistent with the previous report,
cells harboring a Pik3-c2a small hairpin RNA (shRNA) construct
exhibited loss of PI3K-C2a protein (Figure 4A) and diminished9, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1683
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Figure 3. IHR-1 Blocks Smo Accumulation in the Primary Cilium
without Inhibiting SAG-Induced Pathway Response
(A) IHR-NAc, but not IHR-1, blocks SAG-induced depletion of Gpr161 from
the primary cilium. Percent of IMCD3 cells with Gpr161 localized to the
primary cilium (labeled with an acetylated tubulin antibody) is indicated for
each chemical condition (n = 100). Compound concentrations: 0.1 mM
SAG; 10 mM IHR-1; and 10 mM IHR-NAc. Data are mean + SEM of three
fields.
(B) IHR-NAc, but not IHR-1, blocks Smo-mediated disengagement of Gli3
proteolytic processing and Sufu/Gli interaction. NIH 3T3 cells were treated
with SAG and IHR-1 or IHR-NAc. Cellular lysates isolated 24 hr later were
either directly subjected to western blot analysis or immunoprecipitation with a
Sufu antibody. Controls for Sufu immunoprecipitation are provided in Fig-
ure S5. IgG, immunoglobulin G; IP, immunoprecipitation.
(C) SAG-induced Gli2 accumulation at the ciliary tip is blocked by IHR-
NAc, but not IHR-1. The percent of NIH 3T3 cells with Gli2 at the primary
cilium tip was quantified (n = 50) at each time point subsequent to addition
of SAG (0.1 mM) with or without IHR-1 or IHR-NAc (each 10 mM). Data are
mean + SEM of three fields. Representative images are shown on the
right.
(D) IHR-1 and IHR-NAc both inhibit Smo accumulation in the primary cilium.
Percent of NIH 3T3 cells with endogenous Smo in primary cilia were quan-
tified at each time point as described in (C). Data are mean + SEM of three
fields.
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Figure 4. Loss of PI3K-C2a Uncouples Smo Accumulation and
Activity Induced by SAG
(A) Validation of on-target effect of a lentivirally delivered Pik3c2a shRNA
construct in NIH 3T3 cells.
(B) Representative images of primary cilia and Smo in cells harboring a
Pik3c2a shRNA construct in the presence of SAG.
(C) Quantification of cilia with Smo accumulation in the presence of SAG in
cells treated with a control or Pik3c2a shRNA construct. Data are mean + SEM
of three fields.
(D) SAG induces similar transcription of Ptch1 in cells harboring a control or
Pik3c2a shRNA construct. Data are mean + SEM from triplicate experiments.
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1684 Chemistry & Biology 21, 1680–1689, December 18, 2014 ª2014SAG-induced Smo accumulation in the primary cilium (Figures
4B and 4C). On the other hand, the ability of SAG to promote
transcription of the well-validated Hh target gene Ptch1 surpris-
ingly was not compromised in cells harboring the Pik3-c2a
shRNA (Figure 4D). We find this genetically based observation
to be consistent with our conclusion that Smo can signal from
a subcellular compartment outside of the primary cilium when
activated with SAG.
The cancer-associated Smo mutations W535L (also known as
theM2mutation) and L412F localize to different TMdomains that
form the narrow cavity occupied by Smomodulators such as vis-
modegib and SAG (Figures 5A and 5B; Wang et al., 2013, 2014).
Because IHR-1 likely binds to the heptahelical cavity, we initiated
studies to determine if IHR-1 and IHR-NAcmay be useful against
the constitutively active SmoM2 and SmoL412F molecules. WeElsevier Ltd All rights reserved
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Figure 5. Extraciliary Oncogenic Smo Con-
tributes to Deviant Gli Activation
(A) Location of two cancer-associated Smo muta-
tions superimposed on a crystal structure of the Smo
heptahelical domain (modified from Wang et al.,
2013).
(B) SmoM2 and SmoL412F exhibit similar levels of
activity. The GliBS reporter system was used to
monitor Gli activity in cells. Data are mean + SEM
from triplicate experiments.
(C) IHR-NAc, but not IHR-1, is capable of inhibiting
Hh pathway response induced by SmoM2 and
SmoL412F. The GliBS reporter system was used to
monitor Gli activity in cells overexpressing SmoM2 or
SmoL412F. Data are mean + SEM from triplicate
experiments.
(D) IHR-1 and IHR-NAc both block SmoM2 and
SmoL412F accumulation in the primary cilia. Percent
of cells with SmoM2 localized to the primary cilium
was quantified as before (n = 100). Data are mean +
SEM of three fields.
Chemistry & Biology
Extraciliary Smoothened Activation of Hh Signalingcompared the effects of IHR-1 and IHR-NAc against SmoM2-
and SmoL412F-induced Gli activation at a dose well above their
respective half-maximal inhibitory concentration (IC50s) in Hh-
induced pathway response (Figure 5C). As expected, the US
Food and Drug Administration (FDA)-approved Smo antagonist
Vismodegib promoted a substantial loss of Smo-dependent Gli
activity. Surprisingly, whereas IHR-NAc was as equally effective
as Vismodegib, the presence of IHR-1 had limited impact on
SmoM2 or SmoL412F signaling. The different sensitivity of
SmoM2 to these compounds was also reflected in differences
of Gli3 processing and ciliary Gpr161 levels in SmoM2-express-
ing cells treated with IHR-1 or IHR-NAc (Figures S6A and S6B).
At the same time, whereas IHR-NAc but not IHR-1 compromised
oncogenic Smo activity, both compounds blunted SmoM2 and
SmoL412F accumulation in the primary cilium (Figure 5D).
Thus, our observations suggest that SmoM2 and SmoL412F
like SAG-bound Smo are capable of eliciting Gli activity from
an intracellular compartment outside of the primary cilium.
Finally, we note that a SmoM2 molecule lacking a cilia-localiza-
tion signal was previously shown to be unable to activate Gli
activity, although it is unclear if this inactivity is due to alteredChemistry & Biology 21, 1680–1689, December 18, 2014protein folding as a consequence of Smo
mutagenesis, an inability to engage a
cytoplasmic signaling component, or the
absence of localization to the primary cilium
(Bijlsma et al., 2012).
DISCUSSION
Despite the general acceptance that the pri-
mary cilium functions as a nexus for Hh
signaling in both normal and cancerous
contexts (Berbari et al., 2009; Goetz and
Anderson, 2010; Han et al., 2009; Wong
et al., 2009), our understanding of how this
antenna-like organelle supports to signaling
remains rudimentary. In particular, the pri-
mary cilium’s direct support of Gli activationand proteolytic processing has contributed to the difficulties
in understanding the organelle’s role in the activity of ‘‘upstream’’
pathway components such as Smo (Huangfu and Anderson,
2005; Humke et al., 2010; Liu et al., 2005). Our study has identi-
fied a chemically based strategy for uncoupling Smo accu-
mulation in the primary cilium and Gli activation and proteolytic
processing regulation (Figure 6). This should facilitate future
studies aimed at dissecting the Smo-dependent signal trans-
duction mechanisms in normal and oncogenic settings by mini-
mizing unwanted perturbations to primary cilium function or
Smo sequence that can confound subsequent data assessment.
Notably, other Smo probes previously shown to exhibit weak-
ened activity for SAG as compared to for Hh-induced pathway
response may reflect similar differences in cell membrane
permeability (Chen et al., 2002b; Frank-Kamenetsky et al., 2002).
Our observations that extraciliary Smo activity can regulate Gli
proteolytic processing and activation suggest that a direct
engagement of Smo with a signaling complex found within the
primary cilium is not a prerequisite for these biochemical events.
Our findings however cannot rule out the possibility that pathway
components presumed to function within the primary ciliummayª2014 Elsevier Ltd All rights reserved 1685
Figure 6. Model of Smo Signaling in Response to SAG, Oncogenic Mutations, and Hh
In the presence of the synthetic Smo agonist SAG or in cancers expressing a constitutively active Smo protein, Gli is predominantly regulated by Smo found in an
extraciliary compartment. On the other hand, Hh-induced Smo activation in the primary ciliummay be dependent upon Smo interaction with an endogenous small
molecule.
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induced Smo activity (Briscoe and Therond, 2013; Nozawa
et al., 2013). The Smo target protein Gpr161 when genetically
ablated results in Gli activation irrespective of whether or not
Smo is present (Mukhopadhyay et al., 2013). Thus, the ciliary
depletion of Gpr161 in cells treated with SAG and IHR-1 likely
contributes to Gli activity observed under these settings.
Conceivably, IHR-1 and IHR-NAc could induce different Smo
conformations that influence Gpr161 behavior that is not re-
flected by Smo ciliary accumulation and Gli activity readouts
alone. This hypothesis could be tested in the future with a greater
understanding of how Smo communicates with Gpr161 and the
advent of biochemical tools for monitoring their signaling activ-
ities. At the same time, we note that the number of subcellular
compartments capable of supporting GPCR activity outside of
the plasma membrane continue to expand as technologies to
monitor their activity improve (Vilardaga et al., 2014). Future
studies relying on faithful biochemical reporters of endogenous
Smo activity when they become available could be leveraged
to visualize the subcellular compartments of Smo activity outside
of the primary cilium plasma membrane.
Our ability to bypass Smo ciliary localization for Gli regulation
using a Smo agonist or activating Smo mutations raises the
question of why Smo accumulation in the primary cilium is
important for Hh-dependent signaling. Given the resemblance
of the Hh receptor Ptch to small-molecule transporters (Taipale
et al., 2002) and Smo sensitivity to a variety of small molecules1686 Chemistry & Biology 21, 1680–1689, December 18, 2014 ª2014including those akin to cell-produced lipids (Nachtergaele
et al., 2012), one possibility is that Smo ciliary accumulation
gates its interaction with an endogenous ligand (see Figure 6).
Indeed, several studies provide evidence for differences in the
abundance of certain bioactive molecules found in the primary
cilium and the plasma membrane (Bielas et al., 2009; Ha et al.,
2014; Jacoby et al., 2009; Janich and Corbeil, 2007; Jin et al.,
2014; Tyler et al., 2009). We hope the findings presented here
will galvanize efforts to identify an endogenous Smo ligand and
contribute to a framework for investigating candidate molecules
that emerge from such efforts.SIGNIFICANCE
The Smo protein is a major drug target in Hh-associated
cancers and represents a growing number of GPCRs that
rely on the primary cilium for signaling activity. Yet the
contribution of Smo ciliary accumulation to Hh-dependent
transcriptional responses remains unclear. Here, we provide
chemical and genetic evidence that oncogenic Smomutants
with constitutive activity can signal without accumulation in
the primary cilium. When considered with the evidence that
Hh-dependent Smo activity is controlled by an endogenous
lipid, our data suggest that Hh influences Smo interaction
with a small molecule compartmentalized by the primary
cilium. Our findings provide a conceptual framework forElsevier Ltd All rights reserved
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protein and possibly other signaling molecules.
EXPERIMENTAL PROCEDURES
Cell Lines and Reagents
The GliBS Hh pathway reporter (provided by P.A. Beachy), 83 CBP Notch
pathway reporter (provided by R. Kopan), and STF Wnt/b-catenin pathway
reporter (provided by R.Moon) were previously described. Smo-mycwas con-
structed in the pcDNA3 backbone using PCR-based cloning. Smo-M2-myc
and SmoL412F-myc were generated from the Smo-myc backbone using
PCR-based mutagenesis. The Frizzled4 (Fzd4) expression construct was pur-
chased from Open Biosystems. BD-cyclopamine was kindly provided by J.K.
Chen. Other Smo modulators used in this study include cyclopamine (Logan
Natural Products), SANT1 (Sigma), and SAG (Alexis Biochemicals). Vismode-
gib was synthesized by C. Chen. ShhN-conditioned medium was prepared as
previously described (Chen et al., 2002b). 3T3-ShhFL and L-Wnt-STF cell lines
were previously described (Chen et al., 2009; Jacob et al., 2011). Caco-2, NIH
3T3, Shh LightII (referred to as LightII cells), C3H10T1/2, Cos-7, and human
embryonic kidney 293 (HEK293) cells were purchased from American Type
Culture Collection. Cell lines provided by other labs are listed as follows:
FLAG-Gli2 and SMO/ cells (J.K. Chen), A1::Smo::GFP (referred to as
Smo-GFP cells; A.P. McMahon), and PTCH1/ (M.P. Scott). For establishing
the SmoM2-myc-NIH 3T3 cell line, Smo-M2-myc cDNA was transfected into
NIH 3T3 cells and cloneswere selected in the presence of 400 mg/ml Geneticin.
Subclones were then isolated from positive clones identified by western blot
analysis for SmoM2-myc expression. SmoL412F-myc cell line was estab-
lished in C3H10T1/2 cells as described above.
Chemical Screen and Reporter-Based Assays
For the primary screen and dose-response test, 7,000 3T3-ShhFL cells in Dul-
becco’s modified Eagle’s medium (DMEM)/3% calf serum (CS) were seeded
into 384-well plates and incubated at 37C for 2 hr. Two hundred thousand
compounds from University of Texas Southwestern Medical Center were
added into each well by a Biomek FX liquid handler (Beckman Coulter Geno-
mics). Luciferase activities were measured by Dual-Luciferase reporter assay
kit (Promega) 72 hr after drug treatment. To test the effects of compounds of
interest in Wnt signaling, 5,000 L-Wnt-STF cells were seeded into 384-well
plates containing diluted compounds. Luciferase activities were measured
48 hr after drug treatment. Similarly, compounds were tested in the Notch
pathway using the 83CBP reporter in cells transfected with Notch intracellular
domain. For the exogenous Hh test, 12,000 LightII cells were seeded into 96-
well plates. After 24 hr, culture medium was replaced with ShhN conditioned
medium/3% CS. Luciferase activities were measured 48 hr after drug treat-
ment. For testing the activity of IHR compounds against SmoM2 and
SmoL412F-induced Hh pathway activity, SmoM2 DNA, SmoL412F DNA, the
GliBS reporter, and a constitutive Renilla luciferase reporter were transfected
into NIH 3T3 cells using Effectene (QIAGEN). For measuring the Hh pathway
IC50 of IHR-1 in PTCH1/ cells, GliBS and Renilla luciferase reporter were
transfected into PTCH1/ mouse embryonic fibroblasts using Effectene.
To measure IC50s of IHR compounds against SAG-induced Hh pathway acti-
vation, LightII cells were seeded into 96-well plates. For all the reporter assays
described above, culture media were replaced with DMEM/3% CS that were
premixed with compounds after cells reached 100% confluency. Luciferase
activities were measured 48 hr after drug treatment. For alkaline phosphatase
assays in C3H10T1/2, cells treated for 5 days in DMEM/3% fetal bovine serum
(FBS) in the presence of IHR compounds were lysed and alkaline phosphatase
activity measured using the SensoLyte pNPP Alkaline Phosphatase Assay Kit
according to manufacturer’s instructions.
Biochemical Assays
For analyzing Gli2 and Gli3 processing, FLAG-Gli2-expressing cells or NIH 3T3
cells were grown to confluence in 6-well plates. Culture medium was switched
to ShhN conditioned medium or 100 nM SAG in the presence or absence of
Smo antagonists in DMEM/3% CS. After 48 hr of treatment with chemicals,
cells were lysed in radio immunoprecipitation assay buffer. For testing Sufu
and Gli3 interaction, the same protocol was followed with the exception ofChemistry & Biology 21, 1680–168cell lysis using PBS with 1% Igepal CA-630 after 24 hr of chemical treatment.
For Sufu immunoprecipitation, Sufu antibody was crosslinked to protein A
agarose beads with dimethyl pimelimidate crosslinker (Thermo Scientific
Pierce). For all the assays described above, whole-cell lysate was resus-
pended in SDS sample loading buffer and heated to 95C for 1 min prior to
SDS-PAGE. Antibodies used for analyzing the blots were: Gli3 (R&D Systems;
AF3690), Flag epitope-tag (Sigma; F1804), PI3K-C2a (BD Transduction Labo-
ratories; 611046), Sufu, a-tubulin, and GAPDH (Cell Signaling Technology;
2522S, 2125S, and 5174S, respectively).
Immunofluorescence
For Gpr161, Smo, or Gli2 cilia localization assays, IMCD3, NIH 3T3, Smo-GFP,
Smo-M2-myc, or SmoL412F-myc cells were grown to confluence on 12 mm
poly-L-lysine precoated glass coverslips (BD Biosciences). The indicated
compounds were dissolved in DMEM/3% CS and then applied to cells for
48 hr or 72 hr. Cells were either fixed in 100% methanol for 5 min at 20C
or in 3.7% formaldehyde for 15min at room temperature. The cells were further
permeabilized in blocking buffer (5% normal goat serum and 0.2% Triton X-
100 in PBS) for 10 min. Coverslips were treated with anti-Smo (provided by
P. A. Beachy), anti-Myc (Cell Signaling Technology; 2272), anti-GFP (MBL
International; 598), anti-Gli2 and anti-Gpr161 (provided by S. Scales; Genen-
tech), and anti-tubulin (Sigma; T6793) in blocking buffer each for 30 min. After
several PBS washes, the coverslips were further incubated with Alexa-488-
conjugated goat anti-rabbit, Alexa-Fluor-594-conjugated goat anti-mouse,
or Hoechst 33342 (Invitrogen) for 30 min. One hundred primary cilia were
scored for the presence of Gpr161, Smo, SmoM2, SmoL412F, and Gli2 in
each experiment.
Flow Cytometry
Fzd4 or Smo-myc DNA was transfected into Cos-7 cells (BD-cyclopamine-
binding assay) or HEK293 cells (IHR-Cy3-binding assay) by using Fugene6
in 6-well plates. Two days after transfection, cells were incubated withmedium
containing fluorescently labeled compounds and the indicated competing
compounds for 1 hr at 37C. Cell pellets were collected after trypsinization
and washed with cold PBS three times. Cells resuspended in cold PBS were
analyzed by flow cytometry on a FACS Calibur (BD Biosciences). Ten thou-
sand cells were sorted for each sample. A fluorescent-positive gate was
selected in areas where minimum fluorescent-positive cells were detected in
Fzd4 DNA-transfected cells.
Statistical Analysis
Unless otherwise noted, error bars represent SEM.
Chemical Synthesis
Synthesis of IHR-1, IHR-Cy3, and IHR-NAc is described in Supplemental
Experimental Procedures.
Caco-2 Cell Permeability
Caco-2 cells were grown to confluence in 12-well transwell plates (Corning Life
Sciences; 3460). Cell confluency wasmeasured byMillicell-ERS volt-ohmme-
ter (Millipore). Caco-2 cell monolayers with transepithelial electric resistance
values greater than 950 ohm3 cm2were used for experiment. Culturemedium
was replaced with 10 mM of compounds in DMEM/3% CS and incubated for
6 hr. Media from the bottom chamber were collected, and drug concentrations
were determined by mass spectrometric analysis as described below.
Parallel Artificial Membrane Permeability
Studies were executed by Cyprotex. Compounds were dissolved in PBS to a
final concentration of 10 mM. A volume of 300 ml of the 10 mM compounds was
added to the donor well of precoated PAMPA plates (BD Biosciences;
353015), and the acceptor well was filled with 200 ml of PBS. The plate was
incubated for 5 hr at 37C. Liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS) was used to analyze the samples of the donor and acceptor
wells. The effective permeability (Pe) was calculated using the following
equation:
effective permeabilityðPeÞ : log Pe = log

 VDVAðVD +VAÞAt ln

1 ½drugA½drugE

;9, December 18, 2014 ª2014 Elsevier Ltd All rights reserved 1687
Chemistry & Biology
Extraciliary Smoothened Activation of Hh Signalingwhere VD and VA are the volumes of the donor and acceptor compartments, A
is the area of themembrane, t is the incubation time, and A and E subscripts on
the concentration term refer to the acceptor and equilibrium concentrations,
respectively.
Mass Spectrometry
One hundred microliters of each sample was mixed with 200 ml of acetoni-
trile containing 300 ng/ml N-benzylbenzamide (Sigma). The samples were
vortexed for 15 s, allowed to sit 10 min at room temperature, and then
centrifuged 5 min at 13,000 rpm. The supernatant was collected and centri-
fuged an additional time before analysis by LC-MS/MS. Standard curves
were prepared using DMEM with 3% CS spiked with known concentrations
of each compound. DMEM containing 3% CS was used to establish the
limit of detection as three times the signal seen in these samples. In gen-
eral, back calculation of standard curve points and quality control samples
were within 15% of theoretical. The limit of quantification was set as the
lowest point on the standard curve for which back calculation yielded
values within 15% of theoretical. Analytical methods were developed to
detect IHR-1 and IHR-NAc using an Applied Biosystems/MDS Sciex 3200
QTRAP mass spectrometer coupled to a Shimadzu Prominence LC. All
compounds were detected as singly charged species and one daughter
ion. The following transitions were monitored: IHR-1 454.8–173.0 and
IHR-NAc 476.1–173.1. N-benzylbenzamide was used as an internal stan-
dard (transition 212.1–91.1). Chromatography was performed using an Agi-
lent ZORBAX XDB-C18 column (5 microns; 4.6 3 50 mm) and the following
gradient conditions: 0–1 min 5% buffer B; 1–1.5 min gradient to 100%
buffer B; 1.5–3 min 100% buffer B; 3–3.5 min gradient to 5% buffer B;
and 3.5–5 min 5% buffer B. For IHR-1 and IHR-NAc, buffer A consisted
of 100% dH2O + 0.1% formic acid and buffer B consisted of 100%
acetonitrile + 0.1% formic acid.
Pik3-C2a Silencing
An shRNA construct with the Pik3-C2a sequence 50-GGCAAGATATGT
TAGCTTT-30 was purchased from Thermo Scientific. Pik3-C2a shRNA lenti-
virus was produced in 293T cells. Filtered and concentrated virus-laden me-
dium was incubated with NIH 3T3 cells for 48 hr. Infected NIH 3T3 cells
were selected with puromycin (2 mg/ml) for 7 days. Cells with no more than
three passages following were used for experiments.
RT-PCR
3T3-ShhFL cells were grown to confluence in 6-well plates. Culture medium
was replaced with IHR compounds (2.5 mM) in 3% CS and incubated at
37C for 48 hr. For cDNA preparation, Trizol RNA extraction and ProtoScript
M-MuLV First Strand cDNA Synthesis Kit (New England BioLabs) were used.
We used 100%, 80%, 60%, and 40% of cDNA in the PCR reactions. Primers
sequences were GAPDH forward: ATCCTGCACCACCAACT, GAPDH reverse:
TGCCTGCTTCACCACCTT, Ptch1 forward: ACTGTCCAGCTACCCCAATG,
and Ptch1 reverse: CATCATGCCAAAGAGCTCAA. For PI3K-C2a studies,
Ptch1 forward: GGAAGGGGCAAAGCTACAGT and Ptch1 reverse: TCCACC
GTAAAGGAGGCTTA.
Chemically Induced SmoM2 Maturation Assay
Smo-myc and SmoM2-myc DNA were transfected into Cos-7 cells using
Fugene 6. Twenty-four hours after transfection, indicated Smo antagonists
were added at the described concentration. Cells were lysed in PBS with
1% Igepal CA-630 and protease inhibitors 24 hr later. SDS sample loading
buffer was added to whole-cell lysates and heated to 50C for 10 min.
Enzymatic deglycosylation of protein was achieved with 1 ml of Endo H
(Sigma) added to 30 ml of whole-cell lysate in sample loading buffer and
incubating at 37C for 4 hr. For Smo cell surface biotinylation, transfected
Cos-7 cells were washed with ice-cold PBS and incubated in ice-cold PBS
containing 2 mM Sulfo-NHS-SS-Biotin (Pierce) for 30 min. Biotinylation
was quenched by washing and incubating cells with ice-cold PBS contain-
ing 100 mM glycine for 10 min. Cells were then lysed in PBS with 1%
Igepal CA-630 and protease inhibitors. Agarose beads crosslinked to
streptavidin (Sigma) were used to pull down biotinylated proteins. Bound
proteins were recovered in sample loading buffer and separated by
SDS-PAGE.1688 Chemistry & Biology 21, 1680–1689, December 18, 2014 ª2014Radiolabeled SmoM2 Pulse-Chase Experiment
pBSK or SmoM2-myc was transfected into Cos-7 cells using Fugene6 in 6-
well plates. Two days after transfection, the cells were washed with PBS twice
and were incubated with 1 ml of 10% dialyzed FBS in L-methionine- and L-
cysteine-free DMEM. After 1 hr incubation at 37C, the cells were pulsed
with 1,000 mCi/ml of S35-Met/Cys protein labeling mix (NEG072014MC; Perki-
nElmer) for 15 min. Cells were washed with 33 PBS before replacing the me-
diumwith 2ml of 10%FBS in the presence or absence of 10 mMof IHR-NAc. At
different chasing time point, cells were lysed in PBS/1% Igepal CA-630/prote-
ase inhibitors and Smo immunoprecipitated using an anti-Myc (Santa Cruz
Biotechnology; SC-40) antibody.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and six figures and can be found with this article online at http://dx.doi.org/
10.1016/j.chembiol.2014.10.013.
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